EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery

Jun-Jie Wang, Ya Gao, Xin-Qian Ji, Jia-Yi Yin, Meng-Zhi Zhang, Bo Wang, Hui-Min Liu, Siqi Feng iD, Ning Wang iD, Guo-Liang Lu iD, Yan Li, Piet Herdewijn und 3 weitere

Medicinal Research Reviews · 2026-09 · 46 (5) · 1257-1278

DOI: 10.1002/med.70052 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 08.05.2026. Verfasst von Jun-Jie Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Key Laboratory of Advanced Drug Preparation Technolo…. Hauptthemen laut MEDLINE: Histone Deacetylases, Antineoplastic Agents, Proteolysis, Drug Discovery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Foundation of Henan Province, National Natural Science Foundation of China, International Science and Technology Cooperation Project of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histone deacetylases (HDACs) are key epigenetic regulators involved in a variety of cancers, rendering them attractive therapeutic targets. Although several HDAC inhibitors have achieved clinical success, challenges such as poor isoform selectivity, acquired resistance, and off‐target toxicity limit their broader application. Proteolysis‐targeting chimeras (PROTACs) represent an innovative therapeutic strategy that enables ubiquitin–proteasome–mediated degradation of HDACs. This approach enhances specificity, overcomes resistance mechanisms, including those resulting from point mutations or persistent target activity, and enables sustained suppression at low concentrations, owing to its catalytic and event‐driven mode of action. This review summarizes the structural classification and biological functions of HDACs and surveys recent advances in the design of HDAC‐directed PROTACs. Key emphasis is placed on rational warhead selection, linker optimization, and the strategic choice of E3 ligase recruiters to guide degradation efficiency and isoform specificity. Representative degraders are evaluated for their pharmacological characteristics and antitumor efficacy across diverse malignancies. Current challenges and future directions for the development of HDAC degraders as clinically viable agents are also discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone DeacetylasesAntineoplastic AgentsProteolysisDrug DiscoveryHumansHistone Deacetylase InhibitorsAnimalsProteolysis Targeting ChimeraNeoplasms

Stichwörter der Autor:innen

HDACPROTACcancer therapyepigenetic modulationtargeted protein degradation

Substanzen

Histone DeacetylasesAntineoplastic AgentsHistone Deacetylase InhibitorsProteolysis Targeting Chimera

Autor:innen und Institutionen

  • State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Key Laboratory of Henan Province for Smal…
  • School of Chinese Medicine, University of Hong Kong, Hong Kong.
  • Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • Maurice Wilkins Centre, The University of Auckland, Auckland, New Zealand.
  • Department of Biomedicine and Medical Diagnostics, School of Science, Auckland University of Technology, Auckland, New Zealand.
  • XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Siqi Feng, Ning Wang, Guo-Liang Lu, Xing-Jie Dai

Förderung

  • Natural Science Foundation of Henan Province
  • National Natural Science Foundation of China
  • International Science and Technology Cooperation Project of Henan Province
  • The Young Top Talent Program from Henan Association for Science and Technology
  • R&D of Key Project of Henan Province
  • Key Scientific and Technological Projects of Henan Province

Zitieren

APA

Wang, J. J., Gao, Y., Ji, X. Q., Yin, J. Y., Zhang, M. Z., Wang, B., Liu, H. M., Feng, S., Wang, N., Lu, G. L., Li, Y., Herdewijn, P., Zheng, Y. C., Yan, P., & Dai, X. J. (2026). Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery. Medicinal Research Reviews, 46(5), 1257-1278. https://doi.org/10.1002/med.70052

Vancouver

Wang JJ, Gao Y, Ji XQ, Yin JY, Zhang MZ, Wang B, et al. Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery. Medicinal Research Reviews. 2026;46(5):1257-1278. doi:10.1002/med.70052

BibTeX
@article{Wang2026,
  author = {Wang, Jun-Jie and Gao, Ya and Ji, Xin-Qian and Yin, Jia-Yi and Zhang, Meng-Zhi and Wang, Bo and Liu, Hui-Min and Feng, Siqi and Wang, Ning and Lu, Guo-Liang and Li, Yan and Herdewijn, Piet and Zheng, Yi-Chao and Yan, Peng and Dai, Xing-Jie},
  title = {Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery},
  journal = {Medicinal Research Reviews},
  year = {2026},
  volume = {46},
  number = {5},
  pages = {1257--1278},
  doi = {10.1002/med.70052}
}
Kostenlos starten →